The multi-site prescription opioid addiction treatment study: 18-month outcomes

Jennifer S Potter, Jessica A. Dreifuss, Elise N. Marino, Scott E. Provost, Dorian R. Dodd, Lindsay S. Rice, Garrett M. Fitzmaurice, Margaret L. Griffin, Roger D. Weiss

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. Participants from the treatment trial (N. = 252/653) completed an 18-month follow-up telephone assessment. Multivariable analyses examined associations between participant characteristics and key indicators of month-18 status: opioid abstinence, DSM-IV opioid dependence, and opioid agonist treatment. Overall, participants showed improvement from baseline to month 18: 49.6% were abstinent in the previous 30. days, with only 16.3% opioid-dependent. Some participants, however, had initiated past-year heroin use (n. = 9) or opioid injection (n. = 17). Most participants (65.9%) engaged in substance use disorder treatment during the past year, most commonly opioid agonist therapy (48.8%). Of particular interest in this population, multivariable analysis showed that greater pain severity at baseline was associated with opioid dependence at 18. months. In conclusion, although opioid use outcomes during the treatment trial were poor immediately following a buprenorphine-naloxone taper compared to those during 12. weeks of buprenorphine-naloxone stabilization, opioid use outcomes at 18-month follow-up showed substantial improvement over baseline and were comparable to the rate of successful outcomes during buprenorphine-naloxone stabilization in the treatment trial.

Original languageEnglish (US)
Pages (from-to)62-69
Number of pages8
JournalJournal of Substance Abuse Treatment
Volume48
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Opioid Analgesics
Prescriptions
Therapeutics
Heroin
Random Allocation
Telephone
Diagnostic and Statistical Manual of Mental Disorders
Population
Substance-Related Disorders
Counseling
Randomized Controlled Trials
Pain
Injections

Keywords

  • Buprenorphine
  • Clinical trial
  • Follow-up
  • Prescription opioids
  • Substance use disorder
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Cite this

Potter, J. S., Dreifuss, J. A., Marino, E. N., Provost, S. E., Dodd, D. R., Rice, L. S., ... Weiss, R. D. (2015). The multi-site prescription opioid addiction treatment study: 18-month outcomes. Journal of Substance Abuse Treatment, 48(1), 62-69. https://doi.org/10.1016/j.jsat.2014.07.009

The multi-site prescription opioid addiction treatment study : 18-month outcomes. / Potter, Jennifer S; Dreifuss, Jessica A.; Marino, Elise N.; Provost, Scott E.; Dodd, Dorian R.; Rice, Lindsay S.; Fitzmaurice, Garrett M.; Griffin, Margaret L.; Weiss, Roger D.

In: Journal of Substance Abuse Treatment, Vol. 48, No. 1, 01.01.2015, p. 62-69.

Research output: Contribution to journalArticle

Potter, JS, Dreifuss, JA, Marino, EN, Provost, SE, Dodd, DR, Rice, LS, Fitzmaurice, GM, Griffin, ML & Weiss, RD 2015, 'The multi-site prescription opioid addiction treatment study: 18-month outcomes', Journal of Substance Abuse Treatment, vol. 48, no. 1, pp. 62-69. https://doi.org/10.1016/j.jsat.2014.07.009
Potter, Jennifer S ; Dreifuss, Jessica A. ; Marino, Elise N. ; Provost, Scott E. ; Dodd, Dorian R. ; Rice, Lindsay S. ; Fitzmaurice, Garrett M. ; Griffin, Margaret L. ; Weiss, Roger D. / The multi-site prescription opioid addiction treatment study : 18-month outcomes. In: Journal of Substance Abuse Treatment. 2015 ; Vol. 48, No. 1. pp. 62-69.
@article{72ef8261bc01425b8c4c977df5a94104,
title = "The multi-site prescription opioid addiction treatment study: 18-month outcomes",
abstract = "Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. Participants from the treatment trial (N. = 252/653) completed an 18-month follow-up telephone assessment. Multivariable analyses examined associations between participant characteristics and key indicators of month-18 status: opioid abstinence, DSM-IV opioid dependence, and opioid agonist treatment. Overall, participants showed improvement from baseline to month 18: 49.6{\%} were abstinent in the previous 30. days, with only 16.3{\%} opioid-dependent. Some participants, however, had initiated past-year heroin use (n. = 9) or opioid injection (n. = 17). Most participants (65.9{\%}) engaged in substance use disorder treatment during the past year, most commonly opioid agonist therapy (48.8{\%}). Of particular interest in this population, multivariable analysis showed that greater pain severity at baseline was associated with opioid dependence at 18. months. In conclusion, although opioid use outcomes during the treatment trial were poor immediately following a buprenorphine-naloxone taper compared to those during 12. weeks of buprenorphine-naloxone stabilization, opioid use outcomes at 18-month follow-up showed substantial improvement over baseline and were comparable to the rate of successful outcomes during buprenorphine-naloxone stabilization in the treatment trial.",
keywords = "Buprenorphine, Clinical trial, Follow-up, Prescription opioids, Substance use disorder, Treatment",
author = "Potter, {Jennifer S} and Dreifuss, {Jessica A.} and Marino, {Elise N.} and Provost, {Scott E.} and Dodd, {Dorian R.} and Rice, {Lindsay S.} and Fitzmaurice, {Garrett M.} and Griffin, {Margaret L.} and Weiss, {Roger D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jsat.2014.07.009",
language = "English (US)",
volume = "48",
pages = "62--69",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The multi-site prescription opioid addiction treatment study

T2 - 18-month outcomes

AU - Potter, Jennifer S

AU - Dreifuss, Jessica A.

AU - Marino, Elise N.

AU - Provost, Scott E.

AU - Dodd, Dorian R.

AU - Rice, Lindsay S.

AU - Fitzmaurice, Garrett M.

AU - Griffin, Margaret L.

AU - Weiss, Roger D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. Participants from the treatment trial (N. = 252/653) completed an 18-month follow-up telephone assessment. Multivariable analyses examined associations between participant characteristics and key indicators of month-18 status: opioid abstinence, DSM-IV opioid dependence, and opioid agonist treatment. Overall, participants showed improvement from baseline to month 18: 49.6% were abstinent in the previous 30. days, with only 16.3% opioid-dependent. Some participants, however, had initiated past-year heroin use (n. = 9) or opioid injection (n. = 17). Most participants (65.9%) engaged in substance use disorder treatment during the past year, most commonly opioid agonist therapy (48.8%). Of particular interest in this population, multivariable analysis showed that greater pain severity at baseline was associated with opioid dependence at 18. months. In conclusion, although opioid use outcomes during the treatment trial were poor immediately following a buprenorphine-naloxone taper compared to those during 12. weeks of buprenorphine-naloxone stabilization, opioid use outcomes at 18-month follow-up showed substantial improvement over baseline and were comparable to the rate of successful outcomes during buprenorphine-naloxone stabilization in the treatment trial.

AB - Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. Participants from the treatment trial (N. = 252/653) completed an 18-month follow-up telephone assessment. Multivariable analyses examined associations between participant characteristics and key indicators of month-18 status: opioid abstinence, DSM-IV opioid dependence, and opioid agonist treatment. Overall, participants showed improvement from baseline to month 18: 49.6% were abstinent in the previous 30. days, with only 16.3% opioid-dependent. Some participants, however, had initiated past-year heroin use (n. = 9) or opioid injection (n. = 17). Most participants (65.9%) engaged in substance use disorder treatment during the past year, most commonly opioid agonist therapy (48.8%). Of particular interest in this population, multivariable analysis showed that greater pain severity at baseline was associated with opioid dependence at 18. months. In conclusion, although opioid use outcomes during the treatment trial were poor immediately following a buprenorphine-naloxone taper compared to those during 12. weeks of buprenorphine-naloxone stabilization, opioid use outcomes at 18-month follow-up showed substantial improvement over baseline and were comparable to the rate of successful outcomes during buprenorphine-naloxone stabilization in the treatment trial.

KW - Buprenorphine

KW - Clinical trial

KW - Follow-up

KW - Prescription opioids

KW - Substance use disorder

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84922819834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922819834&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2014.07.009

DO - 10.1016/j.jsat.2014.07.009

M3 - Article

C2 - 25189089

AN - SCOPUS:84922819834

VL - 48

SP - 62

EP - 69

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 1

ER -